<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04319536</url>
  </required_header>
  <id_info>
    <org_study_id>B300201942076</org_study_id>
    <nct_id>NCT04319536</nct_id>
  </id_info>
  <brief_title>Integrated Genetic and Functional Analysis of the Female Microbiome in a Flemish Cohort</brief_title>
  <acronym>Isala</acronym>
  <official_title>Integrated Genetic and Functional Analysis of the Female Microbiome in a Flemish Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the project is to improve our knowledge on the stability and temporal dynamics of
      the Flemish female microbiome (vagina, skin and saliva) in relation to different lifestyle
      factors and environmental conditions and to establish certain individual and social risk
      factors that can influence the healthy microbiome. Therefore, microbial DNA from swabs will
      be isolated via commercially available DNA extraction kits, followed by Illumina MiSeq
      sequencing in order to identify the microbial species present in these samples. Special
      attention will go to microbial species that are overrepresented in the healthy populations as
      potential health promoting microbes (i.e. probiotics).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in microbial communities colonizing the vagina, skin and saliva between healthy individuals measured with Illumina MiSeq</measure>
    <time_frame>up to 5 years</time_frame>
    <description>After metagenomic shotgun and amplicon sequencing with the Illumina MiSeq, bio-informatic tools will be used to analyse taxonomic and functional data. The investigators will specifically screen for health-promoting and pathogenic taxa that can be associated with specific environmental conditions and lifestyle factors. Additionally, the investigators will pay attention to the dominant members of the vaginal bacterial community (i.e. beneficial microbes such as lactic acid bacteria).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Vaginal Microbiome</condition>
  <condition>Skin Microbiome</condition>
  <condition>Saliva Microbiome</condition>
  <arm_group>
    <arm_group_label>Healthy individuals</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>self-sampling</description>
    <arm_group_label>Healthy individuals</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Microbial DNA will be analysed from swabs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study populations involves healthy women from 18 years and older.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  none

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Lebeer, Professor</last_name>
    <phone>+32 3 265 32 85</phone>
    <email>sarah.lebeer@uantwerpen.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Ahannach</last_name>
    <phone>+32 3 265 32 17</phone>
    <email>sarah.ahannach@uantwerpen.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Antwerp and University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Lebeer, Professor</last_name>
      <phone>+32 3 265 32 85</phone>
      <email>sarah.lebeer@uantwerpen.be</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Ahannach</last_name>
      <phone>+32 3 265 32 17</phone>
      <email>sarah.ahannach@uantwerpen.be</email>
    </contact_backup>
    <investigator>
      <last_name>Sarah Lebeer, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilbert Donders, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Ahannach</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eline Oerlemans, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiteit Antwerpen</investigator_affiliation>
    <investigator_full_name>Ethisch Comit√©, UZA</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Metagenomic sequencing</keyword>
  <keyword>vaginal microbiome</keyword>
  <keyword>skin microbiome</keyword>
  <keyword>saliva microbiome</keyword>
  <keyword>large-scale self-sampling cohort</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Probiotics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

